MIAMI, FL, April 24, 2026

Telomir Pharmaceuticals has announced the successful completion of its acquisition of TELI Pharmaceuticals, securing full global ownership rights to its lead therapeutic candidate Telomir-1 (Telomir-Zn). This strategic transaction represents a critical milestone in consolidating intellectual property and development control, positioning Telomir to accelerate its clinical-stage oncology pipeline. By eliminating prior geographic fragmentation of rights, the company now holds unified worldwide commercialization and development authority, strengthening its ability to execute a cohesive global strategy in cancer therapeutics and age-related disease research.

Strategic Acquisition Strengthens Global Drug Development

The acquisition, structured as a stock-for-stock transaction, establishes TELI as a wholly owned subsidiary of Telomir Pharmaceuticals, enabling the company to streamline operations and align its research, regulatory, and commercialization pathways under a single corporate structure. Previously, rights to Telomir-1 were divided across regions, limiting strategic flexibility. With this consolidation, Telomir can now pursue global partnerships, licensing opportunities, and coordinated clinical development programs more efficiently.

The transaction also includes initial funding of $1.0 million at closing, along with the potential for up to $4.0 million in milestone-based capital contributions, tied to key clinical achievements such as Investigational New Drug (IND) clearance and clinical trial initiation. This funding model aligns financial support with clinical progress, ensuring sustainable development of the company’s lead asset.

Advancing Telomir-1 into Clinical Trials

Advertisement

cGxPJobs Banner

Telomir has recently submitted an IND application to the U.S. Food and Drug Administration (FDA) for Telomir-1, targeting advanced and metastatic triple-negative breast cancer (TNBC)—a highly aggressive cancer subtype with limited treatment options. Pending regulatory clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy, focusing on safety, tolerability, and early efficacy signals. Telomir-1 is a small-molecule investigational therapy designed to target epigenetic and metabolic pathways, including modulation of intracellular metal homeostasis, mitochondrial function, and genomic stability.

These mechanisms are believed to play a critical role in cancer progression, making Telomir-1 a promising next-generation therapeutic candidate in precision oncology. The transition into clinical trials marks a pivotal step toward validating its therapeutic potential in human patients, potentially opening new treatment avenues for difficult-to-treat cancers.

Positioning for Growth in Precision Oncology

The acquisition underscores Telomir’s broader vision to establish itself as a leader in innovative small-molecule therapeutics targeting complex diseases such as cancer, aging, and degenerative disorders. By securing full control over Telomir-1, the company gains the flexibility to optimize development timelines, expand into global markets, and explore strategic collaborations with pharmaceutical partners. Industry experts note that such consolidation strategies are increasingly critical in the biopharmaceutical sector, where intellectual property alignment and global scalability are key drivers of success.

With a strong focus on precision medicine and targeted therapies, Telomir is well-positioned to capitalize on emerging opportunities in oncology and beyond. As the company advances toward clinical-stage development, this acquisition is expected to enhance investor confidence, accelerate innovation, and strengthen its competitive position in the rapidly evolving biotech landscape.

Source: Telomir Pharmaceuticals press release